PepMix™ SARS-CoV-2 (S-RBD BA.2.75.2) Peptide Pool

PepMix™ SARS-CoV-2 (S-RBD BA.2.75.2)

US$551.20

Excluding tax and shipping fees

In stock

Description

About PepMix™ SARS-CoV-2 (S-RBD BA.2.75.2)

Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) through Receptor Binding Domain of Spike Glycoprotein - contains mutation: G339H, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, G446S, N460K, S477N, T478K, E484A, F486S, Q498R, N501Y, Y505H of SARS-CoV-2 (Severe Acute Respiratory Syndrome-related coronavirus 2) - Lineage B.1.1.529, BA.2.75.2 Omicron sub-variant.

PepMix™ SARS-CoV-2 (S-RBD BA.2.75.2) - Specifications

Amount: 25 µg (approx. 15 nmol) / peptide (for stimulation of up to 2,5 x 108 cells)

Purity: Research Plus Grade: each peptide is guaranteed to be main product (HPLC/MS) - (equivalent to an average purity of 70%)

Delivery Format: Freeze-dried in glass vial

Application(s): T-cell immunity

Condition(s)/Topic(s): Respiratory infection, Covid-19, Infection, Severe acute respiratory syndrome (SARS)

Standard Delivery Time: 2-5 days

Visit our webpage for more information on SARS-CoV-2, its mutations & variants and our corresponding products.

Are you interested in your own custom PepMix? Choose your sequence, amount, purity and pool format. We will assist you along the way. Custom PepMix Peptide Pools.

PepMix™ Peptide PoolsProtein-spanning mixtures of overlapping peptides (PepMix™) are extremely efficient for- Antigen-specific T cell stimulation in T cell assays (e.g. in ELISpot, ICS, cell-mediated cytotoxicity or proliferation assays)- In-vitro T cell expansion- Dendritic cell pulsing- Immune monitoring- Cellular immune response profiling- T cell epitope identification- Standardization of T cell assays

Benefits of PepMix™- Each peptide quality controlled and guaranteed for identity and purity- CoA and HPLC-MS data available- High batch-to-batch consistency- No false positive T cell responses by contaminating deletion peptides- No toxic inhibition of T cell responses due to stringent purification of each peptide- Minimization of endotoxin contamination due to low bioburden process- ADCF policy in place- HLA independent stimulation (with antigen spanning peptide pools)

References

References for PepMix™ SARS-CoV-2 (S-RBD BA.2.75.2)

ReferencesRead References with PepMix™ Peptide Pools for Infectious Diseases COVID-19 related PepMixes™ PepMix™ Control Pools

Application NotesCross-reactive T cells enhance immune responses in SARS-CoV-2 infection and vaccinationLoyal et al (2021) Full textPeptide Tools to Support the Fight against COVID-19Alem et al (2020) Full textCEFX/EFX Ultra SuperStim Pools: Superior positive controls for T-cell assays with broad MHC-allele and antigen coverageEckey et al. (2017) Full textDeveloping Multi-HIV Antigen Specific T-Cells as a Component of a Cure StrategyLam et al. (2015) Full textPeptide-stimulated Expansion of Virus-specific T cells For Preventative Treatment After Allogeneic Stem Cell TransplantationGary et al. (2015) Full textPepMix™ Peptide Pools for Clinical Applications: T Cell Therapy for Viral Infections after Hematopoietic Stem Cell TransplantKeirnan et al. (2012) Full textCytomegalovirus Protein Spanning PepMix™ Peptide Pools to Discover Changes in T-Cell Immunity in the Aging PopulationKern (2012) Full text

Testimonials "To establish a novel role for myeloid derived suppressor cells (Pallett et al, Nat. Med. 2015) in chronic viral infection, we utilised the PepMix CEF Pool (extended) as well as a custom synthesized PepMix spanning the core region of HBV genotype D . Whereas, the CEF peptide pool consists of 32 peptides, each corresponding to a defined HLA class I-restricted T-cell epitope from Cytomegalo, Epstein-Barr, and Influenza virus, the latter custom PepMix included 15meric peptides overlapping by 10 amino acids. Specifically this composition enabled us to monitor both the antiviral CD8+ and CD4+ T cell responses in chronic HBV infection and the non-antigen specific T cells that are known to mediate immunopathology in the liver. Our entire experience with JPT, from ordering/delivery to use in the lab was excellent. Not only were the reagents able to perform reliably and consistently in vitro from batch to batch, the customer and technical support provided was continually available and efficient when needed. JPT will remain our go-to company for purchasing peptides." Dr. Laura J Pallett, Infection and Immunity, University College London, UK

Documentation

Documentation for PepMix™ SARS-CoV-2 (S-RBD BA.2.75.2)

Protocol_PepMix.pdf

PM-SARS-2-S-RBD-BA.2.75.2-1.pdf

Properties

Properties of PepMix™ SARS-CoV-2 (S-RBD BA.2.75.2)

25 ug (approx. 15 nmol) / peptide for stimulation of 2,5 x 108 cells, 25 µg (approx. 15 nmol) / peptide (for stimulation of up to 2,5 x 108 cells)

T-cell immunity

PepMix Peptide Pools, PepMix Peptide Pools Infections

Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)

Freeze-dried in glass vial

SARS-CoV-2 (Severe Acute Respiratory Syndrome-related coronavirus 2)

Receptor Binding Domain of Spike Glycoprotein

Research Plus Grade: each peptide is guaranteed to be main product (HPLC/MS)

No

Further Information to PepMix™ SARS-CoV-2 (S-RBD BA.2.75.2)

Values

RVQPTESIVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSKLKPFERDISTEIYQAGNKPCNGVAGSNCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF Copy Sequence Show complete Sequence Show trimmed Sequence

Related Products

Related Products

PepMix™ SARS-CoV-2 (S-RBD XBB.1.5)

US$525.20

PepMix™ SARS-CoV-2 (S-RBD BQ.1.1)

PepMix™ SARS-CoV-2 (S-RBD BF.7)

PepMix™ SARS-CoV-2 (S-RBD BA.2.75)